Determine the Effects of Prone Positioning and NO in COVID-19 ARDS by EIT

Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05715762
Collaborator
(none)
20
1
12.3
1.6

Study Details

Study Description

Brief Summary

We aims to investigate the effects of prone positioning and nitric oxide inhalation in adult patients who is diagnosed with COVID-19 associated acute respiratory distress syndrome by electrical impedance tomography.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: prone postion
  • Drug: NO inhalation

Detailed Description

The investigators aim to investigate the effects of prone positioning and nitric oxide inhalation in adult patients who is diagnosed with COVID-19 associated acute respiratory distress syndrome by electrical impedance tomography (EIT).

The EIT assessment is performed in patients ventilated in supine position, supine position with NO inhalation for 1 hour, prone position for 1 hour, prone position for 2 hours with NO inhalation for 1 hour, prone position for 3 hours, prone position for 16 hours, re-supine position for 3 hours. Arterial blood gas (ABG) analysis results, ventilator parameters and hemodynamic parameters are also recorded at each time point.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Determine the Effects of Prone Positioning and Nitric Oxide in Adult COVID-19 Patients With ARDS by Electrical Impedance Tomography
Actual Study Start Date :
Dec 21, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Ventilation in supine position

Patients are ventilated in supine position.

Ventilation in supine position and NO inhalation

Patients are ventilated in supine position with NO inhalation for 1 hour.

Drug: NO inhalation
NO inhalation at 20 ppm

Ventilation in prone position for 1 hour

Patients are ventilated in prone position for 1 hour.

Behavioral: prone postion
ventilation at prone positioning
Other Names:
  • PPV
  • Ventilation in prone position for 2 hours plus NO inhalation for 1 hour

    Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour.

    Behavioral: prone postion
    ventilation at prone positioning
    Other Names:
  • PPV
  • Drug: NO inhalation
    NO inhalation at 20 ppm

    Ventilation in prone position for 3 hours

    Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 1 hour.

    Behavioral: prone postion
    ventilation at prone positioning
    Other Names:
  • PPV
  • Ventilation in prone position for 16 hours

    Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 14 hours.

    Behavioral: prone postion
    ventilation at prone positioning
    Other Names:
  • PPV
  • Ventilation in re-supine position for 3 hours

    Patients are ventilated in supine position for 3 hours followed by ventilation in prone position for 16 hours.

    Outcome Measures

    Primary Outcome Measures

    1. oxygenation status [1 day]

      To evaluate the oxygenation parameters

    2. regional distribution of pulmonary perfusion [1 day]

      To evaluate the effect of prone positon and NO inhalation on pulmonary blood flow distribution.

    3. regional distribution of pulmonary ventilation [1 day]

      To evaluate the effect of prone positon and NO inhalation on pulmonary vetilation distribution.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • adult patients who have COVID-19-associated acute respiratory distress syndrome
    Exclusion Criteria:
    • patients who refuse to participate in the study; unable to use EIT, such as open-chest surgery with chest tube placement; have contraindication for prone positioning, including pregnant, post-abdomen surgery within a week; hypercapnic respiratory failure.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zhongshan Hospital, Fudan University Shanghai Shanghai China 200032

    Sponsors and Collaborators

    • Shanghai Zhongshan Hospital

    Investigators

    • Study Chair: Ming Zhong, PhD, Fudan University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Shanghai Zhongshan Hospital
    ClinicalTrials.gov Identifier:
    NCT05715762
    Other Study ID Numbers:
    • eit20221221
    First Posted:
    Feb 8, 2023
    Last Update Posted:
    Feb 8, 2023
    Last Verified:
    Dec 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Shanghai Zhongshan Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 8, 2023